Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13977164 | 1.00 | ACACB (0.32) | ACACBALDH1A1 | |
| SCHEMBL13860726 | 0.78 | ALDH1A1 (0.32) | ACACBALDH1A1 | |
| SCHEMBL13976844 | 0.78 | ALDH1A1 (0.32) | ACACBALDH1A1 | |
| SCHEMBL27553731 | 0.76 | ACACB (0.34) | ACACBALDH1A1 | |
| SCHEMBL13977162 | 0.75 | ACACB (0.33) | ACACBALDH1A1 | |
| SCHEMBL5239679 | 0.75 | ACACB (0.35) | ACACBALDH1A1 | |
| SCHEMBL14764721 | 0.74 | — | — | |
| SCHEMBL14764723 | 0.74 | — | — | |
| SCHEMBL6184495 | 0.73 | ACACB (0.32) | ACACB | |
| SCHEMBL6183397 | 0.73 | ACACB (0.34) | ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150065490-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| US-20090264459-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-10-22 | — | — | US | disclosed |
| EP-1529038-B1 | BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | NOVARTIS AG (CH) | 2009-10-07 | — | — | EP | disclosed |
| EP-2037915-A2 | PHENOL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | Novartis AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008000483-A2 | PHENOL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | NOVARTIS AG (CH) | 2008-01-03 | — | — | WO | disclosed |
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | CUENOUD BERNARD | 2007-10-25 | — | — | US | disclosed |
| EP-1715860-A1 | COMBINATION OF BENZOTHIAZOL-2-ONE BETA2 ADRENOCEPTOR AGONISTS AND CORTICOSTEROIDS FOR THE TREATMENT OF RESPIRATORY DISEASES | Novartis AG (CH) | 2006-11-02 | — | — | EP | disclosed |
| US-20060106075-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | NOVARTIS AG (CH) | 2006-05-18 | — | — | US | disclosed |
| WO-2005074924-A1 | COMBINATION OF BENZOTHIAZOL-2-ONE BETA2 ADRENOCEPTOR AGONISTS AND CORTICOSTEROIDS FOR THE TREATMENT OF RESPIRATORY DISEASES | NOVARTIS AG (CH) | 2005-08-18 | — | — | WO | disclosed |
| EP-1529038-A1 | BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | Novartis AG (CH) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004016601-A1 | BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | NOVARTIS AG (CH) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | ADRB2, ADRB1, ADRA2C | ACACB 1932/4885ALDH1A1 829/4885 |
| US-20060106075-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | ADRB2, ADRB1, ADRA2C | ACACB 1932/4885ALDH1A1 829/4885 |
| US-20090264459-A1 | Organic Compounds | CFTR, AOX1, OR10J3 | ACACB 3456/4885ALDH1A1 208/4885 |
| US-20150065490-A1 | ORGANIC COMPOUNDS | ADRB2, ADRA2C, ADRB1 | ACACB 1296/4885ALDH1A1 226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.